142P Long-term follow-up of neoadjuvant dual anti-HER2 therapy with trastuzumab and lapatinib plus paclitaxel, with or without endocrine therapy for HER2-positive primary breast cancer: Neo-LaTH (JBCRG-16) study.
Saved in:
| Title: | 142P Long-term follow-up of neoadjuvant dual anti-HER2 therapy with trastuzumab and lapatinib plus paclitaxel, with or without endocrine therapy for HER2-positive primary breast cancer: Neo-LaTH (JBCRG-16) study. |
|---|---|
| Authors: | Fujisawa, T.1 (AUTHOR), Masuda, N.2 (AUTHOR), Yamamoto, N.3 (AUTHOR), Iwata, H.4 (AUTHOR), Bando, H.5 (AUTHOR), Aruga, T.6 (AUTHOR), Tokunaga, E.7 (AUTHOR), Ohtani, S.8 (AUTHOR), Takano, T.9 (AUTHOR), Inoue, K.10 (AUTHOR), Suganuma, N.11 (AUTHOR), Takada, M.12 (AUTHOR), Aogi, K.13 (AUTHOR), Sakurai, K.14 (AUTHOR), Shigematsu, H.15 (AUTHOR), Kuroi, K.16 (AUTHOR), Haga, H.17 (AUTHOR), Ohno, S.18 (AUTHOR), Morita, S.19 (AUTHOR), Toi, M.20 (AUTHOR) |
| Source: | Annals of Oncology. 2021 Supplement 5, Vol. 32, pS422-S422. 1p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 152688771 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: 142P Long-term follow-up of neoadjuvant dual anti-HER2 therapy with trastuzumab and lapatinib plus paclitaxel, with or without endocrine therapy for HER2-positive primary breast cancer: Neo-LaTH (JBCRG-16) study. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Fujisawa%2C+T%2E%22">Fujisawa, T.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Masuda%2C+N%2E%22">Masuda, N.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Yamamoto%2C+N%2E%22">Yamamoto, N.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Iwata%2C+H%2E%22">Iwata, H.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bando%2C+H%2E%22">Bando, H.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Aruga%2C+T%2E%22">Aruga, T.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Tokunaga%2C+E%2E%22">Tokunaga, E.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ohtani%2C+S%2E%22">Ohtani, S.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Takano%2C+T%2E%22">Takano, T.</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Inoue%2C+K%2E%22">Inoue, K.</searchLink><relatesTo>10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Suganuma%2C+N%2E%22">Suganuma, N.</searchLink><relatesTo>11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Takada%2C+M%2E%22">Takada, M.</searchLink><relatesTo>12</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Aogi%2C+K%2E%22">Aogi, K.</searchLink><relatesTo>13</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sakurai%2C+K%2E%22">Sakurai, K.</searchLink><relatesTo>14</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Shigematsu%2C+H%2E%22">Shigematsu, H.</searchLink><relatesTo>15</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kuroi%2C+K%2E%22">Kuroi, K.</searchLink><relatesTo>16</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Haga%2C+H%2E%22">Haga, H.</searchLink><relatesTo>17</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ohno%2C+S%2E%22">Ohno, S.</searchLink><relatesTo>18</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Morita%2C+S%2E%22">Morita, S.</searchLink><relatesTo>19</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Toi%2C+M%2E%22">Toi, M.</searchLink><relatesTo>20</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2021 Supplement 5, Vol. 32, pS422-S422. 1p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=152688771 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.annonc.2021.08.423 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 1 StartPage: S422 Titles: – TitleFull: 142P Long-term follow-up of neoadjuvant dual anti-HER2 therapy with trastuzumab and lapatinib plus paclitaxel, with or without endocrine therapy for HER2-positive primary breast cancer: Neo-LaTH (JBCRG-16) study. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Fujisawa, T. – PersonEntity: Name: NameFull: Masuda, N. – PersonEntity: Name: NameFull: Yamamoto, N. – PersonEntity: Name: NameFull: Iwata, H. – PersonEntity: Name: NameFull: Bando, H. – PersonEntity: Name: NameFull: Aruga, T. – PersonEntity: Name: NameFull: Tokunaga, E. – PersonEntity: Name: NameFull: Ohtani, S. – PersonEntity: Name: NameFull: Takano, T. – PersonEntity: Name: NameFull: Inoue, K. – PersonEntity: Name: NameFull: Suganuma, N. – PersonEntity: Name: NameFull: Takada, M. – PersonEntity: Name: NameFull: Aogi, K. – PersonEntity: Name: NameFull: Sakurai, K. – PersonEntity: Name: NameFull: Shigematsu, H. – PersonEntity: Name: NameFull: Kuroi, K. – PersonEntity: Name: NameFull: Haga, H. – PersonEntity: Name: NameFull: Ohno, S. – PersonEntity: Name: NameFull: Morita, S. – PersonEntity: Name: NameFull: Toi, M. IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 09 Text: 2021 Supplement 5 Type: published Y: 2021 Identifiers: – Type: issn-print Value: 09237534 Numbering: – Type: volume Value: 32 Titles: – TitleFull: Annals of Oncology Type: main |
| ResultId | 1 |
